Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaust Limited ( (AU:NUZ) ) has provided an update.
Neurizon Therapeutics Limited announced a webinar to update shareholders on its Q1 FY2026 results and progress in advancing NUZ-001 towards the HEALEY ALS Platform Trial. The company has successfully submitted and received acceptance from the U.S. FDA to lift the clinical hold, allowing entry into the trial. Neurizon has strengthened its financial position with a $5.2 million share placement and a $1.5 million secured loan. The company is also expanding global engagement by participating in industry conferences to build relationships with potential partners and the ALS community.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neuron disease. Neurizon aims to accelerate access to effective ALS treatments and explore broader neurodegenerative applications through international collaborations and rigorous clinical programs.
Average Trading Volume: 774,472
Technical Sentiment Signal: Sell
Current Market Cap: A$61.47M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.